FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz
The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.
Tag Archives: Pulmonary Embolism
-
-
Vici Venous Stent Recall Follows Reports of Stent Migration
Nearly 32,000 stents use to prevent blockages in the veins are being recalled due to the risk of migration and patient injury.
-
Investigation of Xeljanz Cancer and Heart Risks Launched in Canada
Growing concerns have led to Health Canada announcing a Xeljanz safety review, to determine whether more warnings or actions are needed following studies suggesting the ulcerative colitis drug could increase…
-
Xeljanz Cancer Warnings Leave More Questions Than Answers
New Xeljanz research links the drug to cancer risks, but has not yet led to a warning for users as to which types of cancer they may face.
-
Xeljanz Heart and Cancer Concerns May Be Impacting FDA Review of Rinvoq for Psoriatic Arthritis
The FDA may be delaying approval for the drug Rinvoq to be used as a psoriatic arthritis drug due to its close ties to Xeljanz, which has been linked to…
-
Pfizer Files Lawsuit Over Xeljanz Generic Application
Pfizer filed a patent lawsuit over an alleged attempt to create a generic version of Xeljanz shortly after the FDA announced new concerns about the drug's safety.
-
Xeljanz Problems Highlighted in Study Data May Lead to New FDA Restrictions: Report
The FDA is weighing new restrictions on Xeljanz, following clinical trial data linking the drug to an increased risk of heart problems and cancer, according to a new report.
-
Xeljanz Side Effects May Increase Risk of Cancer, Serious Heart Problems: FDA Alert
A new FDA warning indicates Xeljanz side effects may increase the risk of heart problems, including heart attacks, and cancer in patients over 50.
-
Aspirin Just As Good As Other Blood Thinners At Preventing Clots Following Hip, Knee Joint Surgery
A new study finds that aspirin is just as safe and effective as more powerful blood thinners at preventing life-threatening blood clots following surgery, but is far more cost effective.
-
FDA Approves High-Dose, Extended-Release Version of Xeljanz, Despite Blood Clot Risks
The FDA has approved higher dose formulations of extended release Xeljanz, despite concerns over the risk of potentially fatal blood clots.